A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope
The rational design of HIV-1 immunogens to trigger the development of broadly neutralizing antibodies (bNAbs) requires understanding the viral evolutionary pathways influencing this process. An acute HIV-1-infected individual exhibiting >50% plasma neutralization breadth developed neutralizing an...
Gespeichert in:
Veröffentlicht in: | Journal of virology 2024-03, Vol.98 (3), p.e0172023 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 3 |
container_start_page | e0172023 |
container_title | Journal of virology |
container_volume | 98 |
creator | Joshi, Vinita R Claiborne, Daniel T Pack, Melissa L Power, Karen A Newman, Ruchi M Batorsky, Rebecca Bean, David J Goroff, Matthew S Lingwood, Daniel Seaman, Michael S Rosenberg, Eric Allen, Todd M |
description | The rational design of HIV-1 immunogens to trigger the development of broadly neutralizing antibodies (bNAbs) requires understanding the viral evolutionary pathways influencing this process. An acute HIV-1-infected individual exhibiting >50% plasma neutralization breadth developed neutralizing antibody specificities against the CD4-binding site (CD4bs) and V1V2 regions of Env gp120. Comparison of pseudoviruses derived from early and late autologous
sequences demonstrated the development of >2 log resistance to VRC13 but not to other CD4bs-specific bNAbs. Mapping studies indicated that the V3 and CD4-binding loops of Env gp120 contributed significantly to developing resistance to the autologous neutralizing response and that the CD4-binding loop (CD4BL) specifically was responsible for the developing resistance to VRC13. Tracking viral evolution during the development of this cross-neutralizing CD4bs response identified amino acid substitutions arising at only 4 of 11 known VRC13 contact sites (K282, T283, K421, and V471). However, each of these mutations was external to the V3 and CD4BL regions conferring resistance to VRC13 and was transient in nature. Rather, complete resistance to VRC13 was achieved through the cooperative expression of a cluster of single amino acid changes within and immediately adjacent to the CD4BL, including a T359I substitution, exchange of a potential
-linked glycosylation (PNLG) site to residue S362 from N363, and a P369L substitution. Collectively, our data characterize complex HIV-1
evolution in an individual developing resistance to a VRC13-like neutralizing antibody response and identify novel VRC13-associated escape mutations that may be important to inducing VRC13-like bNAbs for lineage-based immunogens.IMPORTANCEThe pursuit of eliciting broadly neutralizing antibodies (bNAbs) through vaccination and their use as therapeutics remains a significant focus in the effort to eradicate HIV-1. Key to our understanding of this approach is a more extensive understanding of bNAb contact sites and susceptible escape mutations in HIV-1 envelope (
). We identified a broad neutralizer exhibiting VRC13-like responses, a non-germline restricted class of CD4-binding site antibody distinct from the well-studied VRC01-class. Through longitudinal envelope sequencing and Env-pseudotyped neutralization assays, we characterized a complex escape pathway requiring the cooperative evolution of four amino acid changes to confer complete resistance t |
doi_str_mv | 10.1128/jvi.01720-23 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10949433</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2932937143</sourcerecordid><originalsourceid>FETCH-LOGICAL-a376t-1680ee9081a6d9d3d576c8ef8fb8fc223d29db13e6cae84a37fc30261452dd933</originalsourceid><addsrcrecordid>eNp1kctLw0AQxhdRtD5unmWPCqbuK-nmJKX4gqIgvm7LZnditybZmE1b_e9NrYoehIE5zG--Yb4PoX1K-pQyeTKduz6hA0YixtdQj5JURnFMxTrqEcJYFHP5tIW2Q5gSQoVIxCba4lJQRnjSQ49D_HA7ojwq3Avg7HqY4QZC7asA2AWsQ_DG6RYsXrh2go0v6wLeMASja8C1bicL_R6wq_Dl1UNEMVRzKHwNu2gj10WAva--g-7Pz-5Gl9H45uJqNBxHmg-SNqKJJAApkVQnNrXcxoPESMhlnsncMMYtS21GOSRGgxTdUm44YQkVMbM25XwHna5061lWgjVQtY0uVN24Ujfvymun_k4qN1HPfq46n0Qq-FLh8Euh8a8zCK0qXTBQFLoCPwuKpbyrARVL9HiFmsaH0ED-c4cStQxDdWGozzAUW-JHK1yHkqmpnzVVZ8V_7MHvP36Ev5PiH_YeklU</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2932937143</pqid></control><display><type>article</type><title>A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Joshi, Vinita R ; Claiborne, Daniel T ; Pack, Melissa L ; Power, Karen A ; Newman, Ruchi M ; Batorsky, Rebecca ; Bean, David J ; Goroff, Matthew S ; Lingwood, Daniel ; Seaman, Michael S ; Rosenberg, Eric ; Allen, Todd M</creator><contributor>Kirchhoff, Frank</contributor><creatorcontrib>Joshi, Vinita R ; Claiborne, Daniel T ; Pack, Melissa L ; Power, Karen A ; Newman, Ruchi M ; Batorsky, Rebecca ; Bean, David J ; Goroff, Matthew S ; Lingwood, Daniel ; Seaman, Michael S ; Rosenberg, Eric ; Allen, Todd M ; Kirchhoff, Frank</creatorcontrib><description>The rational design of HIV-1 immunogens to trigger the development of broadly neutralizing antibodies (bNAbs) requires understanding the viral evolutionary pathways influencing this process. An acute HIV-1-infected individual exhibiting >50% plasma neutralization breadth developed neutralizing antibody specificities against the CD4-binding site (CD4bs) and V1V2 regions of Env gp120. Comparison of pseudoviruses derived from early and late autologous
sequences demonstrated the development of >2 log resistance to VRC13 but not to other CD4bs-specific bNAbs. Mapping studies indicated that the V3 and CD4-binding loops of Env gp120 contributed significantly to developing resistance to the autologous neutralizing response and that the CD4-binding loop (CD4BL) specifically was responsible for the developing resistance to VRC13. Tracking viral evolution during the development of this cross-neutralizing CD4bs response identified amino acid substitutions arising at only 4 of 11 known VRC13 contact sites (K282, T283, K421, and V471). However, each of these mutations was external to the V3 and CD4BL regions conferring resistance to VRC13 and was transient in nature. Rather, complete resistance to VRC13 was achieved through the cooperative expression of a cluster of single amino acid changes within and immediately adjacent to the CD4BL, including a T359I substitution, exchange of a potential
-linked glycosylation (PNLG) site to residue S362 from N363, and a P369L substitution. Collectively, our data characterize complex HIV-1
evolution in an individual developing resistance to a VRC13-like neutralizing antibody response and identify novel VRC13-associated escape mutations that may be important to inducing VRC13-like bNAbs for lineage-based immunogens.IMPORTANCEThe pursuit of eliciting broadly neutralizing antibodies (bNAbs) through vaccination and their use as therapeutics remains a significant focus in the effort to eradicate HIV-1. Key to our understanding of this approach is a more extensive understanding of bNAb contact sites and susceptible escape mutations in HIV-1 envelope (
). We identified a broad neutralizer exhibiting VRC13-like responses, a non-germline restricted class of CD4-binding site antibody distinct from the well-studied VRC01-class. Through longitudinal envelope sequencing and Env-pseudotyped neutralization assays, we characterized a complex escape pathway requiring the cooperative evolution of four amino acid changes to confer complete resistance to VRC13. This suggests that VRC13-class bNAbs may be refractory to rapid escape and attractive for therapeutic applications. Furthermore, the identification of longitudinal viral changes concomitant with the development of neutralization breadth may help identify the viral intermediates needed for the maturation of VRC13-like responses and the design of lineage-based immunogens.</description><identifier>ISSN: 0022-538X</identifier><identifier>ISSN: 1098-5514</identifier><identifier>EISSN: 1098-5514</identifier><identifier>DOI: 10.1128/jvi.01720-23</identifier><identifier>PMID: 38412036</identifier><language>eng</language><publisher>United States: American Society for Microbiology</publisher><subject>Amino Acids ; Antibodies, Neutralizing ; Broadly Neutralizing Antibodies ; CD4 Antigens - genetics ; env Gene Products, Human Immunodeficiency Virus - genetics ; Epitopes ; HIV Antibodies ; HIV Antigens ; HIV Envelope Protein gp120 - genetics ; HIV Infections ; HIV Seropositivity ; HIV-1 - genetics ; Humans ; Immunology ; Pathogenesis and Immunity</subject><ispartof>Journal of virology, 2024-03, Vol.98 (3), p.e0172023</ispartof><rights>Copyright © 2024 American Society for Microbiology.</rights><rights>Copyright © 2024 American Society for Microbiology. 2024 American Society for Microbiology.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-a376t-1680ee9081a6d9d3d576c8ef8fb8fc223d29db13e6cae84a37fc30261452dd933</cites><orcidid>0000-0002-3032-137X ; 0000-0002-6609-1318 ; 0000-0002-2091-1456</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10949433/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10949433/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38412036$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Kirchhoff, Frank</contributor><creatorcontrib>Joshi, Vinita R</creatorcontrib><creatorcontrib>Claiborne, Daniel T</creatorcontrib><creatorcontrib>Pack, Melissa L</creatorcontrib><creatorcontrib>Power, Karen A</creatorcontrib><creatorcontrib>Newman, Ruchi M</creatorcontrib><creatorcontrib>Batorsky, Rebecca</creatorcontrib><creatorcontrib>Bean, David J</creatorcontrib><creatorcontrib>Goroff, Matthew S</creatorcontrib><creatorcontrib>Lingwood, Daniel</creatorcontrib><creatorcontrib>Seaman, Michael S</creatorcontrib><creatorcontrib>Rosenberg, Eric</creatorcontrib><creatorcontrib>Allen, Todd M</creatorcontrib><title>A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope</title><title>Journal of virology</title><addtitle>J Virol</addtitle><addtitle>J Virol</addtitle><description>The rational design of HIV-1 immunogens to trigger the development of broadly neutralizing antibodies (bNAbs) requires understanding the viral evolutionary pathways influencing this process. An acute HIV-1-infected individual exhibiting >50% plasma neutralization breadth developed neutralizing antibody specificities against the CD4-binding site (CD4bs) and V1V2 regions of Env gp120. Comparison of pseudoviruses derived from early and late autologous
sequences demonstrated the development of >2 log resistance to VRC13 but not to other CD4bs-specific bNAbs. Mapping studies indicated that the V3 and CD4-binding loops of Env gp120 contributed significantly to developing resistance to the autologous neutralizing response and that the CD4-binding loop (CD4BL) specifically was responsible for the developing resistance to VRC13. Tracking viral evolution during the development of this cross-neutralizing CD4bs response identified amino acid substitutions arising at only 4 of 11 known VRC13 contact sites (K282, T283, K421, and V471). However, each of these mutations was external to the V3 and CD4BL regions conferring resistance to VRC13 and was transient in nature. Rather, complete resistance to VRC13 was achieved through the cooperative expression of a cluster of single amino acid changes within and immediately adjacent to the CD4BL, including a T359I substitution, exchange of a potential
-linked glycosylation (PNLG) site to residue S362 from N363, and a P369L substitution. Collectively, our data characterize complex HIV-1
evolution in an individual developing resistance to a VRC13-like neutralizing antibody response and identify novel VRC13-associated escape mutations that may be important to inducing VRC13-like bNAbs for lineage-based immunogens.IMPORTANCEThe pursuit of eliciting broadly neutralizing antibodies (bNAbs) through vaccination and their use as therapeutics remains a significant focus in the effort to eradicate HIV-1. Key to our understanding of this approach is a more extensive understanding of bNAb contact sites and susceptible escape mutations in HIV-1 envelope (
). We identified a broad neutralizer exhibiting VRC13-like responses, a non-germline restricted class of CD4-binding site antibody distinct from the well-studied VRC01-class. Through longitudinal envelope sequencing and Env-pseudotyped neutralization assays, we characterized a complex escape pathway requiring the cooperative evolution of four amino acid changes to confer complete resistance to VRC13. This suggests that VRC13-class bNAbs may be refractory to rapid escape and attractive for therapeutic applications. Furthermore, the identification of longitudinal viral changes concomitant with the development of neutralization breadth may help identify the viral intermediates needed for the maturation of VRC13-like responses and the design of lineage-based immunogens.</description><subject>Amino Acids</subject><subject>Antibodies, Neutralizing</subject><subject>Broadly Neutralizing Antibodies</subject><subject>CD4 Antigens - genetics</subject><subject>env Gene Products, Human Immunodeficiency Virus - genetics</subject><subject>Epitopes</subject><subject>HIV Antibodies</subject><subject>HIV Antigens</subject><subject>HIV Envelope Protein gp120 - genetics</subject><subject>HIV Infections</subject><subject>HIV Seropositivity</subject><subject>HIV-1 - genetics</subject><subject>Humans</subject><subject>Immunology</subject><subject>Pathogenesis and Immunity</subject><issn>0022-538X</issn><issn>1098-5514</issn><issn>1098-5514</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctLw0AQxhdRtD5unmWPCqbuK-nmJKX4gqIgvm7LZnditybZmE1b_e9NrYoehIE5zG--Yb4PoX1K-pQyeTKduz6hA0YixtdQj5JURnFMxTrqEcJYFHP5tIW2Q5gSQoVIxCba4lJQRnjSQ49D_HA7ojwq3Avg7HqY4QZC7asA2AWsQ_DG6RYsXrh2go0v6wLeMASja8C1bicL_R6wq_Dl1UNEMVRzKHwNu2gj10WAva--g-7Pz-5Gl9H45uJqNBxHmg-SNqKJJAApkVQnNrXcxoPESMhlnsncMMYtS21GOSRGgxTdUm44YQkVMbM25XwHna5061lWgjVQtY0uVN24Ujfvymun_k4qN1HPfq46n0Qq-FLh8Euh8a8zCK0qXTBQFLoCPwuKpbyrARVL9HiFmsaH0ED-c4cStQxDdWGozzAUW-JHK1yHkqmpnzVVZ8V_7MHvP36Ev5PiH_YeklU</recordid><startdate>20240319</startdate><enddate>20240319</enddate><creator>Joshi, Vinita R</creator><creator>Claiborne, Daniel T</creator><creator>Pack, Melissa L</creator><creator>Power, Karen A</creator><creator>Newman, Ruchi M</creator><creator>Batorsky, Rebecca</creator><creator>Bean, David J</creator><creator>Goroff, Matthew S</creator><creator>Lingwood, Daniel</creator><creator>Seaman, Michael S</creator><creator>Rosenberg, Eric</creator><creator>Allen, Todd M</creator><general>American Society for Microbiology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3032-137X</orcidid><orcidid>https://orcid.org/0000-0002-6609-1318</orcidid><orcidid>https://orcid.org/0000-0002-2091-1456</orcidid></search><sort><creationdate>20240319</creationdate><title>A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope</title><author>Joshi, Vinita R ; Claiborne, Daniel T ; Pack, Melissa L ; Power, Karen A ; Newman, Ruchi M ; Batorsky, Rebecca ; Bean, David J ; Goroff, Matthew S ; Lingwood, Daniel ; Seaman, Michael S ; Rosenberg, Eric ; Allen, Todd M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a376t-1680ee9081a6d9d3d576c8ef8fb8fc223d29db13e6cae84a37fc30261452dd933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Amino Acids</topic><topic>Antibodies, Neutralizing</topic><topic>Broadly Neutralizing Antibodies</topic><topic>CD4 Antigens - genetics</topic><topic>env Gene Products, Human Immunodeficiency Virus - genetics</topic><topic>Epitopes</topic><topic>HIV Antibodies</topic><topic>HIV Antigens</topic><topic>HIV Envelope Protein gp120 - genetics</topic><topic>HIV Infections</topic><topic>HIV Seropositivity</topic><topic>HIV-1 - genetics</topic><topic>Humans</topic><topic>Immunology</topic><topic>Pathogenesis and Immunity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Joshi, Vinita R</creatorcontrib><creatorcontrib>Claiborne, Daniel T</creatorcontrib><creatorcontrib>Pack, Melissa L</creatorcontrib><creatorcontrib>Power, Karen A</creatorcontrib><creatorcontrib>Newman, Ruchi M</creatorcontrib><creatorcontrib>Batorsky, Rebecca</creatorcontrib><creatorcontrib>Bean, David J</creatorcontrib><creatorcontrib>Goroff, Matthew S</creatorcontrib><creatorcontrib>Lingwood, Daniel</creatorcontrib><creatorcontrib>Seaman, Michael S</creatorcontrib><creatorcontrib>Rosenberg, Eric</creatorcontrib><creatorcontrib>Allen, Todd M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Joshi, Vinita R</au><au>Claiborne, Daniel T</au><au>Pack, Melissa L</au><au>Power, Karen A</au><au>Newman, Ruchi M</au><au>Batorsky, Rebecca</au><au>Bean, David J</au><au>Goroff, Matthew S</au><au>Lingwood, Daniel</au><au>Seaman, Michael S</au><au>Rosenberg, Eric</au><au>Allen, Todd M</au><au>Kirchhoff, Frank</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope</atitle><jtitle>Journal of virology</jtitle><stitle>J Virol</stitle><addtitle>J Virol</addtitle><date>2024-03-19</date><risdate>2024</risdate><volume>98</volume><issue>3</issue><spage>e0172023</spage><pages>e0172023-</pages><issn>0022-538X</issn><issn>1098-5514</issn><eissn>1098-5514</eissn><abstract>The rational design of HIV-1 immunogens to trigger the development of broadly neutralizing antibodies (bNAbs) requires understanding the viral evolutionary pathways influencing this process. An acute HIV-1-infected individual exhibiting >50% plasma neutralization breadth developed neutralizing antibody specificities against the CD4-binding site (CD4bs) and V1V2 regions of Env gp120. Comparison of pseudoviruses derived from early and late autologous
sequences demonstrated the development of >2 log resistance to VRC13 but not to other CD4bs-specific bNAbs. Mapping studies indicated that the V3 and CD4-binding loops of Env gp120 contributed significantly to developing resistance to the autologous neutralizing response and that the CD4-binding loop (CD4BL) specifically was responsible for the developing resistance to VRC13. Tracking viral evolution during the development of this cross-neutralizing CD4bs response identified amino acid substitutions arising at only 4 of 11 known VRC13 contact sites (K282, T283, K421, and V471). However, each of these mutations was external to the V3 and CD4BL regions conferring resistance to VRC13 and was transient in nature. Rather, complete resistance to VRC13 was achieved through the cooperative expression of a cluster of single amino acid changes within and immediately adjacent to the CD4BL, including a T359I substitution, exchange of a potential
-linked glycosylation (PNLG) site to residue S362 from N363, and a P369L substitution. Collectively, our data characterize complex HIV-1
evolution in an individual developing resistance to a VRC13-like neutralizing antibody response and identify novel VRC13-associated escape mutations that may be important to inducing VRC13-like bNAbs for lineage-based immunogens.IMPORTANCEThe pursuit of eliciting broadly neutralizing antibodies (bNAbs) through vaccination and their use as therapeutics remains a significant focus in the effort to eradicate HIV-1. Key to our understanding of this approach is a more extensive understanding of bNAb contact sites and susceptible escape mutations in HIV-1 envelope (
). We identified a broad neutralizer exhibiting VRC13-like responses, a non-germline restricted class of CD4-binding site antibody distinct from the well-studied VRC01-class. Through longitudinal envelope sequencing and Env-pseudotyped neutralization assays, we characterized a complex escape pathway requiring the cooperative evolution of four amino acid changes to confer complete resistance to VRC13. This suggests that VRC13-class bNAbs may be refractory to rapid escape and attractive for therapeutic applications. Furthermore, the identification of longitudinal viral changes concomitant with the development of neutralization breadth may help identify the viral intermediates needed for the maturation of VRC13-like responses and the design of lineage-based immunogens.</abstract><cop>United States</cop><pub>American Society for Microbiology</pub><pmid>38412036</pmid><doi>10.1128/jvi.01720-23</doi><tpages>25</tpages><orcidid>https://orcid.org/0000-0002-3032-137X</orcidid><orcidid>https://orcid.org/0000-0002-6609-1318</orcidid><orcidid>https://orcid.org/0000-0002-2091-1456</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-538X |
ispartof | Journal of virology, 2024-03, Vol.98 (3), p.e0172023 |
issn | 0022-538X 1098-5514 1098-5514 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10949433 |
source | MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central |
subjects | Amino Acids Antibodies, Neutralizing Broadly Neutralizing Antibodies CD4 Antigens - genetics env Gene Products, Human Immunodeficiency Virus - genetics Epitopes HIV Antibodies HIV Antigens HIV Envelope Protein gp120 - genetics HIV Infections HIV Seropositivity HIV-1 - genetics Humans Immunology Pathogenesis and Immunity |
title | A VRC13-like bNAb response is associated with complex escape pathways in HIV-1 envelope |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T09%3A46%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20VRC13-like%20bNAb%20response%20is%20associated%20with%20complex%20escape%20pathways%20in%20HIV-1%20envelope&rft.jtitle=Journal%20of%20virology&rft.au=Joshi,%20Vinita%20R&rft.date=2024-03-19&rft.volume=98&rft.issue=3&rft.spage=e0172023&rft.pages=e0172023-&rft.issn=0022-538X&rft.eissn=1098-5514&rft_id=info:doi/10.1128/jvi.01720-23&rft_dat=%3Cproquest_pubme%3E2932937143%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2932937143&rft_id=info:pmid/38412036&rfr_iscdi=true |